IDEAS home Printed from https://ideas.repec.org/h/nbr/nberch/13995.html
   My bibliography  Save this book chapter

Orphan Drug Designations as Valuable Intangible Assets for IPO Investors in Pharma-Biotech Companies

In: Economic Dimensions of Personalized and Precision Medicine

Author

Listed:
  • Philippe Gorry
  • Diego Useche

Abstract

Orphan Drug (OD) legislation has been implemented with regulatory and financial incentives to encourage drug innovation in order to treat rare diseases. This study aims to test whether OD Designations (ODD) granted by the Food and Drug Administration (FDA) to pharmaceutical and biotechnology start-up companies may be considered as relevant signals in attracting entrepreneurial finance and increasing the amount invested at the time of the Initial Public Offering (IPO) in the US stock markets. We found that the signaling power of ODD is positively and statistically significant for IPO investors in stock markets. Regression results also suggest that ODDs are stronger than patent applications in attracting IPO investors. Scholarly and policy implications are discussed in the light of the signaling theory and drug development policies.
(This abstract was borrowed from another version of this item.)

Suggested Citation

  • Philippe Gorry & Diego Useche, 2018. "Orphan Drug Designations as Valuable Intangible Assets for IPO Investors in Pharma-Biotech Companies," NBER Chapters, in: Economic Dimensions of Personalized and Precision Medicine, pages 305-334, National Bureau of Economic Research, Inc.
    • Handle: RePEc:nbr:nberch:13995
    as

    Download full text from publisher

    File URL: http://www.nber.org/chapters/c13995.pdf
    Download Restriction: no
    ---><---

    Other versions of this item:

    References listed on IDEAS

    as
    1. Jay R. Ritter & Ivo Welch, 2002. "A Review of IPO Activity, Pricing, and Allocations," Journal of Finance, American Finance Association, vol. 57(4), pages 1795-1828, August.
    2. Rzakhanov, Zaur, 2008. "Regulatory policy, value of knowledge assets and innovation strategy: The case of the Orphan Drug Act," Research Policy, Elsevier, vol. 37(4), pages 673-689, May.
    3. Michael Noel & Mark Schankerman, 2013. "Strategic Patenting and Software Innovation," Journal of Industrial Economics, Wiley Blackwell, vol. 61(3), pages 481-520, September.
    4. Manuel Trajtenberg, 1990. "A Penny for Your Quotes: Patent Citations and the Value of Innovations," RAND Journal of Economics, The RAND Corporation, vol. 21(1), pages 172-187, Spring.
    5. Carter, Richard B & Manaster, Steven, 1990. "Initial Public Offerings and Underwriter Reputation," Journal of Finance, American Finance Association, vol. 45(4), pages 1045-1067, September.
    6. Ritter, Jay R, 1984. "Signaling and the Valuation of Unseasoned New Issues: A Comment," Journal of Finance, American Finance Association, vol. 39(4), pages 1231-1237, September.
    7. Useche, Diego, 2014. "Are patents signals for the IPO market? An EU–US comparison for the software industry," Research Policy, Elsevier, vol. 43(8), pages 1299-1311.
    8. Luigi Orsenigo & Valerio Sterzi, 2010. "Comparative Study of the Use of Patents in Different Industries," KITeS Working Papers 033, KITeS, Centre for Knowledge, Internationalization and Technology Studies, Universita' Bocconi, Milano, Italy, revised 2010.
    9. Monica C. Higgins & Ranjay Gulati, 2003. "Getting Off to a Good Start: The Effects of Upper Echelon Affiliations on Underwriter Prestige," Organization Science, INFORMS, vol. 14(3), pages 244-263, June.
    10. LiPuma, Joseph A., 2012. "Internationalization and the IPO performance of new ventures," Journal of Business Research, Elsevier, vol. 65(7), pages 914-921.
    11. Moors, Ellen H.M. & Faber, Jan, 2007. "Orphan drugs: Unmet societal need for non-profitable privately supplied new products," Research Policy, Elsevier, vol. 36(3), pages 336-354, April.
    12. Paul Muller & Julien Pénin, 2007. "Why do firms disclose knowledge and how does it matter?," Springer Books, in: Uwe Cantner & Franco Malerba (ed.), Innovation, Industrial Dynamics and Structural Transformation, pages 149-172, Springer.
    13. Mansfield, Edwin & Schwartz, Mark & Wagner, Samuel, 1981. "Imitation Costs and Patents: An Empirical Study," Economic Journal, Royal Economic Society, vol. 91(364), pages 907-918, December.
    14. I. Krinsky & W. Rotenberg, 1989. "The valuation of initial public offerings," Contemporary Accounting Research, John Wiley & Sons, vol. 5(2), pages 501-515, March.
    15. Hoenen, Sebastian & Kolympiris, Christos & Schoenmakers, Wilfred & Kalaitzandonakes, Nicholas, 2014. "The diminishing signaling value of patents between early rounds of venture capital financing," Research Policy, Elsevier, vol. 43(6), pages 956-989.
    16. Gompers, Paul A, 1995. "Optimal Investment, Monitoring, and the Staging of Venture Capital," Journal of Finance, American Finance Association, vol. 50(5), pages 1461-1489, December.
    17. Higgins, Matthew J. & Stephan, Paula E. & Thursby, Jerry G., 2011. "Conveying quality and value in emerging industries: Star scientists and the role of signals in biotechnology," Research Policy, Elsevier, vol. 40(4), pages 605-617, May.
    18. Certo, S. Trevis & Holmes Jr., R. Michael & Holcomb, Tim R., 2007. "The influence of people on the performance of IPO firms," Business Horizons, Elsevier, vol. 50(4), pages 271-276.
    19. H. Garden & V. Paris & Philippe Gorry, 2016. "Health innovation for rare diseases," Post-Print hal-02152440, HAL.
    20. Joseph Lipuma, 2012. "Internationalization and the IPO performance of new ventures," Post-Print hal-02312661, HAL.
    21. Richard C. Levin & Alvin K. Klevorick & Richard R. Nelson & Sidney G. Winter, 1987. "Appropriating the Returns from Industrial Research and Development," Brookings Papers on Economic Activity, Economic Studies Program, The Brookings Institution, vol. 18(3, Specia), pages 783-832.
    22. Hoenig, Daniel & Henkel, Joachim, 2015. "Quality signals? The role of patents, alliances, and team experience in venture capital financing," Research Policy, Elsevier, vol. 44(5), pages 1049-1064.
    23. Leland, Hayne E & Pyle, David H, 1977. "Informational Asymmetries, Financial Structure, and Financial Intermediation," Journal of Finance, American Finance Association, vol. 32(2), pages 371-387, May.
    24. James C. Brau & Stanley E. Fawcett, 2006. "Initial Public Offerings: An Analysis of Theory and Practice," Journal of Finance, American Finance Association, vol. 61(1), pages 399-436, February.
    25. Tim Loughran & Jay Ritter, 2004. "Why Has IPO Underpricing Changed Over Time?," Financial Management, Financial Management Association, vol. 33(3), Fall.
    26. Chang, Sea Jin, 2004. "Venture capital financing, strategic alliances, and the initial public offerings of Internet startups," Journal of Business Venturing, Elsevier, vol. 19(5), pages 721-741, September.
    27. Lazonick, William & Tulum, Öner, 2011. "US biopharmaceutical finance and the sustainability of the biotech business model," Research Policy, Elsevier, vol. 40(9), pages 1170-1187.
    28. Jay Chok & Jifeng Qian, 2013. "Do Executives' Backgrounds Matter to IPO Investors? Evidence from the Life Science Industry," PLOS ONE, Public Library of Science, vol. 8(5), pages 1-13, May.
    29. Baltagi, Badi H & Khanti-Akom, Sophon, 1990. "On Efficient Estimation with Panel Data: An Empirical Comparison of Instrumental Variables Estimators," Journal of Applied Econometrics, John Wiley & Sons, Ltd., vol. 5(4), pages 401-406, Oct.-Dec..
    30. Mayston, David, 2009. "The determinants of cumulative endogeneity bias in multivariate analysis," Journal of Multivariate Analysis, Elsevier, vol. 100(6), pages 1120-1136, July.
    31. Megginson, William L & Weiss, Kathleen A, 1991. "Venture Capitalist Certification in Initial Public Offerings," Journal of Finance, American Finance Association, vol. 46(3), pages 879-903, July.
    32. Yin, Wesley, 2008. "Market incentives and pharmaceutical innovation," Journal of Health Economics, Elsevier, vol. 27(4), pages 1060-1077, July.
    33. Lerner, Joshua, 1994. "Venture capitalists and the decision to go public," Journal of Financial Economics, Elsevier, vol. 35(3), pages 293-316, June.
    34. Chemmanur, Thomas J & Fulghieri, Paolo, 1994. "Investment Bank Reputation, Information Production, and Financial Intermediation," Journal of Finance, American Finance Association, vol. 49(1), pages 57-79, March.
    35. Windmeijer, Frank, 2005. "A finite sample correction for the variance of linear efficient two-step GMM estimators," Journal of Econometrics, Elsevier, vol. 126(1), pages 25-51, May.
    36. Michael Spence, 1973. "Job Market Signaling," The Quarterly Journal of Economics, President and Fellows of Harvard College, vol. 87(3), pages 355-374.
    Full references (including those not matched with items on IDEAS)

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Useche, Diego, 2014. "Are patents signals for the IPO market? An EU–US comparison for the software industry," Research Policy, Elsevier, vol. 43(8), pages 1299-1311.
    2. Sunny Hahn & Jina Kang, 2017. "Complementary or conflictory?: the effects of the composition of the syndicate on venture capital-backed IPOs in the US stock market," Economia e Politica Industriale: Journal of Industrial and Business Economics, Springer;Associazione Amici di Economia e Politica Industriale, vol. 44(1), pages 77-102, March.
    3. Huyghebaert, Nancy & Xu, Weidong, 2015. "What determines the market share of investment banks in Chinese domestic IPOs?," China Economic Review, Elsevier, vol. 34(C), pages 150-168.
    4. Ozdemir, Ozgur & Upneja, Arun, 2016. "The role of internationalization on the IPO performance of service firms: Examination of initial returns, long-run returns, and survivability," International Business Review, Elsevier, vol. 25(5), pages 997-1009.
    5. Morricone, Serena & Munari, Federico & Oriani, Raffaele & de Rassenfosse, Gaetan, 2017. "Commercialization Strategy and IPO Underpricing," Research Policy, Elsevier, vol. 46(6), pages 1133-1141.
    6. Jeppsson, Hans, 2018. "Initial public offerings, subscription precommitments and venture capital participation," Journal of Corporate Finance, Elsevier, vol. 50(C), pages 650-668.
    7. LiPuma, Joseph A., 2012. "Internationalization and the IPO performance of new ventures," Journal of Business Research, Elsevier, vol. 65(7), pages 914-921.
    8. Wang, Taiyuan & Qureshi, Israr & Deeds, David & Ren, Yi, 2019. "How do technology ventures signal IPO quality? A configurational approach," Journal of Business Research, Elsevier, vol. 99(C), pages 105-114.
    9. Matthew J. Higgins & Paula E. Stephan & Jerry G. Thursby, 2008. "Conveying Quality and Value in Emerging Industries: Star Scientists and the Role of Learning in Biotechnology," NBER Working Papers 14602, National Bureau of Economic Research, Inc.
    10. Andrew J. Leone & Steve Rock & Michael Willenborg, 2007. "Disclosure of Intended Use of Proceeds and Underpricing in Initial Public Offerings," Journal of Accounting Research, Wiley Blackwell, vol. 45(1), pages 111-153, March.
    11. Higgins, Matthew J. & Stephan, Paula E. & Thursby, Jerry G., 2011. "Conveying quality and value in emerging industries: Star scientists and the role of signals in biotechnology," Research Policy, Elsevier, vol. 40(4), pages 605-617, May.
    12. Mousa, Fariss-Terry & Wales, William J. & Harper, Steven R., 2015. "When less is more: EO's influence upon funds raised by young technology firms at IPO," Journal of Business Research, Elsevier, vol. 68(2), pages 306-313.
    13. Reber, Beat & Vencappa, Dev, 2016. "Deliberate premarket underpricing and aftermarket mispricing: New insights on IPO pricing," International Review of Financial Analysis, Elsevier, vol. 44(C), pages 18-33.
    14. Colombo, Massimo G. & Meoli, Michele & Vismara, Silvio, 2019. "Signaling in science-based IPOs: The combined effect of affiliation with prestigious universities, underwriters, and venture capitalists," Journal of Business Venturing, Elsevier, vol. 34(1), pages 141-177.
    15. Reber, Beat, 2017. "Does mispricing, liquidity or third-party certification contribute to IPO downside risk?," International Review of Financial Analysis, Elsevier, vol. 51(C), pages 25-53.
    16. Hall, Bronwyn H. & Lerner, Josh, 2010. "The Financing of R&D and Innovation," Handbook of the Economics of Innovation, in: Bronwyn H. Hall & Nathan Rosenberg (ed.), Handbook of the Economics of Innovation, edition 1, volume 1, chapter 0, pages 609-639, Elsevier.
    17. Jeffrey J. Reuer & Tony W. Tong, 2010. "Discovering Valuable Growth Opportunities: An Analysis of Equity Alliances with IPO Firms," Organization Science, INFORMS, vol. 21(1), pages 202-215, February.
    18. Bostan, Ibrahim & Mian, G. Mujtaba, 2024. "Inventor CEOs and financing of innovation: Evidence from IPOs," Journal of Banking & Finance, Elsevier, vol. 164(C).
    19. Agoraki, Maria-Eleni & Gounopoulos, Dimitrios & Kouretas, Georgios P., 2021. "Market expectations and the impact of credit rating on the IPOs of U.S. banks," Journal of Economic Behavior & Organization, Elsevier, vol. 189(C), pages 587-610.
    20. Marc T. Junkunc & Jonathan T. Eckhardt, 2009. "Technical Specialized Knowledge and Secondary Shares in Initial Public Offerings," Management Science, INFORMS, vol. 55(10), pages 1670-1687, October.

    More about this item

    JEL classification:

    • G11 - Financial Economics - - General Financial Markets - - - Portfolio Choice; Investment Decisions
    • G24 - Financial Economics - - Financial Institutions and Services - - - Investment Banking; Venture Capital; Brokerage
    • I1 - Health, Education, and Welfare - - Health
    • L65 - Industrial Organization - - Industry Studies: Manufacturing - - - Chemicals; Rubber; Drugs; Biotechnology; Plastics
    • O32 - Economic Development, Innovation, Technological Change, and Growth - - Innovation; Research and Development; Technological Change; Intellectual Property Rights - - - Management of Technological Innovation and R&D
    • O34 - Economic Development, Innovation, Technological Change, and Growth - - Innovation; Research and Development; Technological Change; Intellectual Property Rights - - - Intellectual Property and Intellectual Capital

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:nbr:nberch:13995. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: the person in charge (email available below). General contact details of provider: https://edirc.repec.org/data/nberrus.html .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.